Cardiac Positron Emission Tomography (PET)

Cardiac positron emission tomography (PET) uses radionuclide tracers to evaluate heart tissue functioning. It is especially useful for detecting the type of heart disease that reduces blood flow to the heart muscle. It is specific enough to identify injured, yet living heart muscle.

82 Cardiac Perfusion Imaging is known and recognized as a powerful tool in the assessment of coronary artery disease (CAD). The high sensitivity, specificity and accuracy of cardiac perfusion imaging can potentially reduce the costs associated with CAD by decreasing the need for more expensive and higher risk, invasive procedures. CardioGen-82 is the only FDA approved generator-based perfusion agent reimbursed for the evaluation of CAD.

Clinical Indications

  • CAD
  • Chest Pain
  • Abnormal EKG
  • Evaluate PTCA
  • Dilated Cardiomyopathy
  • Analysis of Cardiac Symptom Presentations
  • Chronic Ischemia
  • Post Myocardial Infarction Syndrome
  • Hyperlipidemia
  • Diabetes Mellitus
  • Persistent symptoms post negative SPECT
  • Acute and Chronic Vascular Diseases
  • Myocardial Infarction
  • Identification of areas at risk of myocardial necrosis when compared with FDG viability study
  • Surgical Risk Assessment

Technical Advantages of Cardiac PET/CT

  • Fewer attenuation artifacts
  • Enhanced spatial resolution
  • High quality images
  • Superior resolution
  • Functional imaging of dynamic processes
  • In-vivo, non-invasive measurement of coronary floe in m/min/g
  • Lower radiation exposure
CT Angiogram